

TABLE S2. Possibly related AEs in ≥10% of patients and possibly related selected AEs

	Number of patients, n (%) (N = 81)			
	Total	Grade 1	Grade 2	Grade ≥3
Possibly related AEs in ≥10% of patients				
Rash (grouped term)	48 (59.3)	31 (38.3)	14 (17.3)	3 (3.7)
Paronychia (grouped term)	40 (49.4)	17 (21.0)	23 (28.4)	0
Diarrhea	32 (39.5)	26 (32.1)	4 (4.9)	2 (2.5)
Dry skin (grouped term)	29 (35.8)	22 (27.2)	7 (8.6)	0
White blood cell count decreased	23 (28.4)	4 (4.9)	15 (18.5)	4 (4.9)
Platelet count decreased	20 (24.7)	17 (21.0)	2 (2.5)	1 (1.2)
Stomatitis	19 (23.5)	14 (17.3)	5 (6.2)	0
Anemia	12 (14.8)	3 (3.7)	5 (6.2)	4 (4.9)
Neutrophil count decreased	12 (14.8)	2 (2.5)	6 (7.4)	4 (4.9)
Alanine aminotransferase increased	11 (13.6)	7 (8.6)	1 (1.2)	3 (3.7)
Aspartate aminotransferase increased	11 (13.6)	8 (9.9)	1 (1.2)	2 (2.5)
Possibly related selected AEs				
ILD (grouped term)	5 (6.2)	2 (2.5)	0	3 (3.7)
Hyperglycemia	1 (1.2)	0	1 (1.2)	0
Electrocardiogram QT prolonged	6 (7.4)	4 (4.9)	1 (1.2)	1 (1.2)

Adverse events and possible relation were assessed by the investigator. In this pooled analysis, there were a total of 2 (5.7%) patients who presented grade 5 AEs that occurred in the AURA extension study. These corresponded to two cases of ILD. AEs, adverse events; ILD, interstitial lung disease.